Herlihy Erin P, Kelly John P, Sidbury Robert, Perkins Jonathan A, Weiss Avery H
Department of Surgery, Division of Pediatric Ophthalmology, Seattle Children's Hospital, Seattle, Washington; Department of Ophthalmology, University of Washington, Seattle.
Department of Surgery, Division of Pediatric Ophthalmology, Seattle Children's Hospital, Seattle, Washington; Department of Ophthalmology, University of Washington, Seattle.
J AAPOS. 2016 Feb;20(1):30-3. doi: 10.1016/j.jaapos.2015.10.014.
Periocular infantile hemangiomas (PIH) can induce anisometropic astigmatism, a risk factor for amblyopia. Oral beta-blocker therapy has largely supplanted systemic or intralesional corticosteroids. The purpose of this study was to evaluate the effect and time course of these treatment modalities on visual acuity and induced astigmatism.
The medical records of patients with PIH treated with oral propanolol between November 2008 and July 2013 were retrospectively reviewed for data on visual acuity and astigmatism. Patients with incomplete pre- and post-treatment ophthalmic examinations were excluded. Results were compared to those of a similar cohort treated with intralesional corticosteroid injection.
Mean astigmatism in affected eyes was 1.90 D before propranolol and 1.00 D after; patients showed a monophasic reduction in astigmatism over 12 months. By comparison, patients treated with corticosteroid injection showed a biphasic response, with an immediate steep decrease followed by a slow monophasic decline, paralleling propranolol-treated patients. Oral propranolol treatment caused a 47% reduction in mean induced astigmatism, less than the 63% reduction reported for the cohort treated with corticosteroid. No patient had visual acuity in the affected eye more than 1 standard devation below the age-matched norm, and none experienced significant side effects when treated with oral propranolol.
In this patient cohort oral beta-blocker was well-tolerated. Treatment was therefore often initiated prior to the induction of significant astigmatism, with treatment effects comparable to steroid treatment. Visual outcomes were good. Early treatment may minimize the potential effect of astigmatism on postnatal visual development.
眼周婴儿血管瘤(PIH)可导致屈光参差性散光,这是弱视的一个危险因素。口服β受体阻滞剂疗法已在很大程度上取代了全身或病灶内注射皮质类固醇疗法。本研究的目的是评估这些治疗方式对视力和诱发散光的效果及时间进程。
回顾性分析2008年11月至2013年7月间接受口服普萘洛尔治疗的PIH患者的病历,以获取视力和散光数据。排除治疗前后眼科检查不完整的患者。将结果与接受病灶内注射皮质类固醇治疗的类似队列进行比较。
患眼的平均散光在服用普萘洛尔前为1.90 D,之后为1.00 D;患者的散光在12个月内呈单相降低。相比之下,接受皮质类固醇注射治疗的患者表现出双相反应,即立即急剧下降,随后是缓慢的单相下降,与普萘洛尔治疗的患者相似。口服普萘洛尔治疗使平均诱发散光降低了47%,低于接受皮质类固醇治疗队列报告的63%的降低幅度。没有患者患眼的视力比年龄匹配的正常水平低超过1个标准差,并且接受口服普萘洛尔治疗时无人出现明显副作用。
在这个患者队列中,口服β受体阻滞剂耐受性良好。因此,治疗通常在诱发明显散光之前开始,治疗效果与类固醇治疗相当。视觉预后良好。早期治疗可能会使散光对出生后视觉发育的潜在影响降至最低。